SCHEMBL1030639

SCHEMBL1030639

CCN(CC)c1ccc(C(C)(C)C)cc1N=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
PKM P14618 1/20 0.35
KMT2A Q03164 1/20 0.35
ALDH1A3 P47895 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
CYP2D6 P10635 1/20 0.33
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032660 0.81 CYP1A2 (0.37) HSP90AA1HSP90AB1MAPTSMN1; SMN2ALDH1A1
SCHEMBL1027914 0.78 CYP2D6 (0.40) HSP90AA1HSP90AB1MAPTSMN1; SMN2ALDH1A1
SCHEMBL16247253 0.71 CRHR1 (0.42) HSP90AA1HSP90AB1ALDH1A1CYP1A2CYP2C19
SCHEMBL756089 0.71 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL1029805 0.69 ALDH1A1 (0.57) HSP90AA1HSP90AB1MAPTSMN1; SMN2ALDH1A1
SCHEMBL1028790 0.69 ALDH1A1 (0.47) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL28203965 0.69 MAPT (0.41) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL13690118 0.67 CA2 (0.42) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL13556609 0.67 CA1 (0.42) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL28234441 0.67 ALDH1A1 (0.42) MAPTSMN1; SMN2ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474377-B1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS CHEMTURA CORP (US) 2011-01-19 EP claimed
US-7125475-B2 Nitrosophenols and C-nitrosoanilines as polymerization inhibitors CROMPTON CORPORATION (US) 2006-10-24 US claimed
EP-1474377-A1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS Crompton Corporation (US) 2004-11-10 EP claimed
WO-2003070687-A1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS CROMPTON CORPORATION (US) 2003-08-28 WO claimed
US-20030155227-A1 Nitrosophenols and C-nitrosoanilines as polymerization inhibitors CROMPTON CORPORATION 2003-08-21 US claimed
US-20180361319-A1 METHOD FOR IMPROVED REACTVE MONOMER PRODUCTION WITH MEMBRANE FILTRATION EVONIK DEGUSSA GMBH (DE) 2018-12-20 US disclosed
EP-3197596-B1 METHOD FOR IMPROVED REACTIVE MONOMER PRODUCTION WITH MEMBRANE FILTRATION EVONIK DEGUSSA GMBH (DE) 2018-11-07 EP disclosed
EP-2993164-B1 Phenolic (thio) acetals as inhibitors of the polymerisation of olefinically unsaturated monomers EVONIK DEGUSSA GMBH (DE) 2017-02-15 EP disclosed
EP-2993164-A1 Phenolic (thio) acetals as inhibitors of the polymerisation of olefinically unsaturated monomers Evonik Degussa GmbH (DE) 2016-03-09 EP disclosed
EP-1474377-B1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS CHEMTURA CORP (US) 2011-01-19 EP disclosed
US-7125475-B2 Nitrosophenols and C-nitrosoanilines as polymerization inhibitors CROMPTON CORPORATION (US) 2006-10-24 US disclosed
EP-1474377-A1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS Crompton Corporation (US) 2004-11-10 EP disclosed
WO-2003070687-A1 NITROSOPHENOLS AND C-NITROSOANILINES AS POLYMERIZATION INHIBITORS CROMPTON CORPORATION (US) 2003-08-28 WO disclosed
US-20030155227-A1 Nitrosophenols and C-nitrosoanilines as polymerization inhibitors CROMPTON CORPORATION 2003-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180361319-A1 METHOD FOR IMPROVED REACTVE MONOMER PRODUCTION WITH MEMBRANE FILTRATION PUF60, MAX, SAMM50 HSP90AA1 4497/4885HSP90AB1 4405/4885MAPT 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.